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Introduction: The goal of insulin therapy in patients with either type 1 diabetes  mellitus 
(T1DM) or type 2 diabetes mellitus (T2DM) is to match as closely as possible normal 
 physiologic insulin secretion to control fasting and postprandial plasma glucose. Modifications 
of the insulin molecule have resulted in two long-acting insulin analogs (glargine and detemir) 
and three rapid-acting insulins (aspart, lispro, and glulisine) with improved pharmacokinetic/
pharmacodynamic (PK/PD) profiles. These agents can be used together in basal-bolus therapy 
to more closely mimic physiologic insulin secretion patterns.
Methods: This study reviews effects of the multiple demographic and clinical parameters in the 
insulin analogs glargine, detemir, lispro, aspart, and glulisine in patients with T2DM. A search 
was conducted on PubMed for each major topic considered (effects of injection site, age, race/
ethnicity, obesity, renal or hepatic dysfunction, pregnancy, exercise, drug interactions) using 
the topic words and name of each type of insulin analog. Information was also obtained from 
the prescribing information for each insulin analog.
Results: The PK/PD profiles for insulin analogs may be influenced by many variables including 
age, weight, and hepatic and renal function. However, these variables do not have equivalent 
effects on all long-acting or rapid-acting insulin analogs.
Conclusion: Rapid-acting and long-acting insulin analogs represent major advances in treatment 
for patients with T2DM who require insulin therapy. However, there are potentially important 
PK and PD differences between the two long-acting agents and among the three rapid-acting 
insulin analogs, which should be considered when designing treatment regimens for special 
patient groups.
Keywords: insulin analogs, type 2 diabetes mellitus, pharmacodynamics, pharmacokinetics
Introduction
Type 2 diabetes mellitus (T2DM) is characterized by a marked and progressive 
 disruption of normal physiologic insulin secretion. There are two key aspects of insulin 
secretion in healthy individuals: (1) basal insulin secretion by pancreatic β cells that 
occurs continuously to maintain steady glucose levels for extended periods between 
meals, and (2) prandial secretion in which insulin is rapidly released in an initial 
first-phase spike in response to a meal, followed by prolonged insulin secretion that 
returns to basal levels after 2–3 hours (Figure 1).1–3 Insulin is a potent anabolic hormone 
that binds to insulin receptors to lower blood glucose by facilitating cellular uptake 
of glucose, amino acids, and fatty acids into skeletal muscle and fat and by inhibiting 
the output of glucose from the liver. Insulin increases the expression or activity of 
enzymes that catalyze glycogen, lipid, and protein synthesis, while inhibiting lipolysis 
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and, proteolysis (Figure 2).4,5 In normal healthy individuals, 
physiologic basal and prandial insulin secretions maintain 
euglycemia, which affects fasting plasma glucose (FPG) and 
postprandial plasma glucose (PPG) concentrations.
Basal and prandial insulin secretion are impaired in 
T2DM and early post-meal response is absent.6,7 The loss 
or blunting of this first-phase insulin secretion is important 
in deterioration of glucose tolerance and elevation of PPG 
concentrations.7 Reduction of basal insulin secretion in 
patients with T2DM causes unopposed glucagon secretion by 
pancreatic α-cells, which results in increased hepatic glucose 
output.8,9 These effects cause elevations in FPG. Although 
T2DM is characterized by alterations in insulin secretion, 
this is only one of many pathologic changes observed in 
patients. T2DM is also associated with insulin resistance (IR) 
in peripheral muscle and adipose tissues, which contributes to 
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Figure 1 Mean 24-hour physiologic serum insulin and plasma glucose levels in nondiabetic subjects.3
Reprinted from Am J Med, vol. 113, issue 4, Gerich, Novel insulins: expanding options in diabetes management, pp. 308–316, Copyright (2002), with permission from elsevier.
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Figure 2 The regulation of metabolism by insulin.5
Reprinted from Nature, vol. 414, issue 6865, Saltiel and Kahn, Insulin signalling and the regulation of glucose and lipid metabolism, pp. 799–806, Copyright (2001), with 
permission from Nature Publishing Group. 
Abbreviation: FFA, free fatty acids.
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significantly elevated FPG.7 Thus, altered insulin  secretion, 
increased hepatic glucose output, and IR all contribute to 
loss of glucose control in patients with T2DM.
Treatment of patients with T2DM may include oral and 
injectable therapies. This paper focuses on insulin therapy 
for the pharmacotherapeutic treatment of T2DM.
Many patients with T2DM ultimately require insulin 
therapy to maintain glycemic control. A survey including 
information from 61,890 patients with T2DM indicated 
that at ,1, 1–5, 6–10, 11–15, 16–20, and .20 years after 
diagnosis 11%, 15%, 36%, 57%, 71%, and 76% of patients, 
respectively, were receiving insulin monotherapy or insulin 
in combination with oral antidiabetes agents.10,11 The goal 
of insulin therapy in type 1 diabetes (T1DM) or T2DM is to 
match as closely as possible physiologic insulin secretion to 
control FPG and PPG.9 Before the development of insulin 
analogs, achieving this goal was limited by the characteristics 
of insulin preparations.
Neutral protamine Hagedorn (NPH) insulin and regular 
human insulin (RHI) can replace or supplement basal and 
prandial insulin to control PPG and FPG, but they have 
important limitations,3,12–14 and use of these agents does 
not result in a good approximation of physiologic insulin 
secretion. The pharmacokinetic/pharmacodynamic (PK/PD) 
profile for NPH has a distinct peak; it does not match peak-
less physiologic basal insulin secretion and requires multiple 
daily injections (Table 1).12 RHI is administered to control 
PPG concentrations, but its PK profile is not ideal for 
achieving this goal. It reaches peak activity relatively slowly 
(.60 minutes after dosing),13 and must be administered at 
least 30 minutes before meals to control PPG.15 Its duration 
of action is approximately 6–8 hours and, as a result, plasma 
insulin levels remain elevated for longer periods after meals, 
increasing risk for hypoglycemia and insulin stacking with 
more than twice-daily dosing (Table 1).3,13,15–17 One benefit of 
the longer action profile of RHI is that it may be used more 
effectively in patients with gastroparesis and slowed gastric 
emptying who have delayed carbohydrate absorption.18 
Overall, however, combination therapy using NPH and RHI 
does not closely approximate physiologic insulin secretion, 
may provide limited control over FPG and PPG, and may be 
associated with high risk for hypoglycemia.3
Modifications of the insulin molecule have resulted in two 
long-acting insulin analogs (glargine and detemir) and three 
rapid-acting insulin analogs (aspart, lispro, and  glulisine) 
with improved PK/PD profiles (Table 1).4,19–24 These agents 
can be used together in basal-bolus therapy to more closely 
mimic physiologic insulin secretion patterns.3,15,25 Although 
they may be used together, one difference with insulin 
analogs compared with human insulin, such as NPH and 
RHI, is that long-acting analogs may not be mixed in the 
same syringe with any other insulin preparations and this 
requires separate injections.
Glargine and high-dose detemir have more predictable 
flat, time-action, profiles that provide up to 24-hour glucose 
control and lower risk for hypoglycemia than NPH in patients 
with T2DM.26–29 Equivalent doses of glargine and detemir 
may provide 24-hour glycemic control in patients with 
T2DM, although occasionally, higher doses of detemir are 
required.30,31 Rapid-acting insulin analogs have a faster onset 
and shorter duration of action (DOA) than RHI and provide 
better control of PPG and may decrease risk for post-meal 
hypoglycemia.28,32–34
The most recent consensus statement from the American 
Association of Clinical Endocrinologists and the American 
College of Endocrinology strongly recommends against 
Table 1 Insulin pharmacokinetic profilesa
Insulin typeb Onset Peak DOA Cmax 
(mU/mL)
Tmax 
(min)
Appearance
Rapid-acting 
 Lispro19 
 Aspart20 
 Glulisine21,22
 
5–15 minutes 
10–20 minutes 
20 minutes
 
30–60 minutes 
40–50 minutes 
1 hour
 
3–4 hours 
3–5 hours 
4 hours
 
116 
82.1 
82
 
30–90 
40–50 
30–90
 
Clear, colorless 
Clear, colorless 
Clear, colorless
Short-acting 
 Regular3,13,15–17
 
30 minutes
 
60–120 minutes
 
6–8 hours
 
51
 
50–120
 
Clear, colorless
Intermediate-acting 
 NPH12
 
1–2 hours
 
3–8 hours
 
12–15 hours
 
22.8
 
360–720
 
Cloudy, white
Long-acting 
 Glarginec,23 
 Detemird,4,24
 
1–2 hours 
1.6 hours
 
Flatc 
Flatc
 
∼24 hours 
Up to 24 hoursc
 
18.9 
149 pmol/L
 
None 
None
 
Clear, colorless 
Clear, colorless
Notes: aestimates only; effects in individual patients vary; ball values are for subcutaneous administration of the insulin analog; ccannot be mixed with any other insulin – 
requires a separate injection; dvaries by dose; higher dose – longer duration.
Abbreviations: DOA, duration of action; NPH, neutral protamine Hagedorn.
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NPH insulin in favor of longer-acting insulin analogs.35 This 
guideline states that use of NPH as a basal insulin has been 
superseded by the synthetic analogs glargine and detemir, 
which both provide a relatively peakless profile for approxi-
mately 24 hours. Although NPH is less expensive, the analogs 
offer the opportunity for more physiologic action profiles. 
The guideline also notes that insulin analogs yield better 
reproducibility and consistency between and within patients, 
and a corresponding reduction in risk of hypoglycemia.35 
Variability in the efficacy and dosing of insulin analogs may 
occur in certain patient populations, thereby complicating 
diabetes treatment and increasing the risk of adverse effects. 
The purpose of this paper is to review the PK/PD character-
istics of long- and rapid-acting insulin analogs and their use 
in special patient populations with T2DM.
Methods
Several methods were employed in order to identify the most 
relevant articles to include. A PubMed literature search was 
conducted to identify peer-reviewed articles published in 
English from 2000 to 2011. Search terms included “insulin 
analogs,” “insulin lispro,” “insulin aspart,” “insulin glulisine,” 
“insulin glargine,” “insulin detemir,” “regular human insulin,” 
“neutral protamine Hagedorn,” and “NPH.” Each of these 
terms was individually paired with the following terms: 
“pharmacokinetics,” “pharmacodynamics,” “type 2 diabetes,” 
“Caucasian,” “African American,”  “Japanese,” “Latino,” “His-
panic,” “Asian,” “obese,” “renal,” “kidney,” “nephropathy,” 
“hepatic,” “liver,” “pregnant,” “gestational diabetes mellitus,” 
“exercise,” “physical,” and “comorbidity.” The US prescribing 
information for each insulin was also searched for informa-
tion related to each topic. Publications that addressed only 
oral antidiabetes drugs were not included, nor were letters, 
commentaries, or case studies.
Once the abstracts were reviewed, complete versions 
of articles that met the criteria noted above were obtained. 
The contributing authors and the impact factors of the 
journals in which articles were published were noted, and 
the study design, methodology, and clinical relevance were 
assessed. Once publications were identified as relevant, 
their bibliographies were reviewed and key references were 
obtained and assessed for inclusion.
The intent of this article is to address the clinical benefits 
of insulin for specific populations. As a result, a limitation 
of this analysis is that if an abstract of an article  identified 
during literature searches did not provide information 
 pertaining to such patient groups, the article was not 
included. Additionally, relevant publications may not have 
been  identified in the PubMed search because they were not 
indexed in a manner that met the search criteria employed. 
Another potential limitation to consider is that the identifica-
tion of relevant publications was performed by the author, 
and therefore has the potential for subjectivity.
Results
A total of 118 articles were obtained. After excluding 
publications that did not meet the pre-identified criteria or 
failed to provide information relevant to this manuscript, the 
results and clinical implications provided in 38 references 
were included.
Factors affecting pharmacokinetic/
pharmacodynamic profiles  
for insulin analogs
Several factors may influence the PK/PD of insulin 
 analogs in patients with T2DM. Two of the most impor-
tant are insulin dose and injection site. The area under the 
curve (AUC) and DOA for long- and rapid-acting insulin 
 analogs generally increase with dose elevation.24,34,36,37 For 
example, results from a study assessing PK of detemir of 
0.15, 0.3, and 0.6 units/kg indicated dose-proportional 
effects on reduction in endogenous glucose production and 
increased glucose uptake across this dose range.37 Results 
from a  second study indicated that the DOA of detemir 
also increased proportionally with dose and was 5.7, 12.1, 
19.9, 22.7, and 23.2 hours for doses of 0.1, 0.2, 0.4, 0.8, and 
1.6 units/kg, respectively.24 Glargine doses of 0.5, 1.0, 1.5, 
and 2.0 units/kg also produced dose-proportional increases 
in DOA as reflected by rate of glucose disappearance in a 
euglycemic clamp study.38
The injection site of insulin analogs may also affect 
their PK/PD profiles. Generally, deeper subcutaneous (SC) 
injections cause more rapid insulin diffusion and absorption.39 
High SC fat may slow absorption, altering or delaying the 
time-action profile.32 Severely obese patients may require 
elevated daily insulin doses and multiple split insulin 
injections at each dosing interval to improve insulin action 
and predictability (eg, glargine or detemir 140 units, delivered 
in two injections of 70 units once daily, with both injection 
sites separated by 2 inches). Moreover, obese patients with 
significant central obesity may also require longer needles for 
effective insulin delivery to prevent leakage of large doses 
in this dense SC area.
Insulin is most often injected into the SC fat in the 
abdomen, thigh, or deltoid. Studies exploring long-acting 
insulin analogs indicate differing effects on PK/PD profiles. 
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Results for glargine suggest no clinically signif icant 
differences in DOA whether injected into the abdomen, 
thigh, or deltoid.23 For detemir, absolute bioavailability is 
64%, 59%, and 65% following SC injection in the abdo-
men, thigh, and deltoid, respectively. The detemir AUC 
and maximum plasma concentration (C
max
) are significantly 
higher (approximately 10% and 20%, respectively) after 
SC injection in the abdomen or deltoid, compared with the 
thigh.40 As with any insulin preparations, heat or muscle 
activity can increase the absorption rate. Abdominal SC tis-
sue provides a predictable absorption rate not as dependent 
on heat, exercise, or activity compared with muscle and is a 
preferred site for patients with T2DM.41
Studies evaluating rapid-acting insulin analogs suggest 
that injection site has only a moderate effect on their PK/PD 
profiles. Results for aspart indicate short time to C
max
 and 
time to maximal concentration (T
max
) and more rapid onset 
of PD effect with thigh injection versus deltoid or abdominal 
injection.42 Studies with lispro have shown an earlier T
max
 and 
higher C
max
 with abdominal versus deltoid or thigh injection.43 
The time-concentration profile for glulisine is not signifi-
cantly influenced by injection site, and bioavailability is 73% 
after SC injection into the abdomen, 71% after injection into 
the deltoid, and 68% after injection into the thigh.21
Overall, having patients rotate insulin injections within 
the same location each week (eg, in the abdomen as the 
preferred site or thigh or deltoid) will decrease variability 
and improve predictability of insulin response.
Changes in insulin analog PK/PD profiles 
in special patient populations
Understanding how PK/PD profiles for specific insulin 
analogs may be altered in special patient populations may 
permit proactive dosing adjustments to achieve or maintain 
glycemic control and decrease the risk of hypoglycemia. 
Information about the issues addressed in this section is 
not available for all insulin analogs. For each topic, both 
published papers and US prescribing information were 
reviewed.
elderly patients
Variability in PK related to declines in renal and/or hepatic 
function may complicate dosing of insulin and other 
medications in elderly patients.44 Clearance (removal 
from the bloodstream) of detemir is decreased in the 
elderly ($68 years of age) and AUC is increased, predispos-
ing them to hypoglycemia. More frequent self-monitoring of 
blood glucose (BG) is required, especially before operating 
a vehicle or heavy machinery, and insulin dose adjustments 
may be needed.4 Alterations in PK in elderly patients have 
not been studied for glargine. Among the rapid-acting insulin 
analogs, alterations in PK/PD have been studied only for 
aspart. Its PK/PD profile is the same in young and elderly 
($65 years old) patients.45 Overall, if clearance is reduced 
and/or AUC increased, the risk for hypoglycemia is elevated, 
and matching carbohydrate meal content to insulin dose is a 
necessity to prevent low BG.
Specific racial and ethnic groups
The PK/PD profile for detemir is consistent in Caucasian, 
African American, Japanese, and Hispanic groups.4,46 
Results from a study of 16 African American, 16 Hispanics/
Latinos, and 16 Caucasian patients evaluated with 16-hour 
isoglycemic glucose clamps and detemir doses of 0.3, 0.6, and 
1.2 units/kg indicated linear PK and no differences among 
racial or ethnic groups.46 Results for glargine indicate more 
rapid absorption in Japanese than Caucasian subjects with 
T2DM.47 PK studies with glargine have not been conducted 
in other racial or ethnic groups.
Assessment of the effects of race or ethnicity on the 
PK/PD of rapid-acting insulin analogs has been limited. 
Results for aspart indicate that its profile in Japanese patients 
does not differ significantly from that in Caucasians,48 and 
those for glulisine have shown that Japanese subjects have 
higher initial exposure (33% higher by AUC over a period 
of 1 hour) versus Caucasians,21 potentially allowing for 
smaller glulisine doses in Japanese patients with T2DM. 
The effects of race or ethnicity on the PK/PD of lispro have 
not been studied.
Obesity
The prevalence of overweight and obesity among patients 
with T2DM are both high. The Study to Help Improve 
Early evaluation and management of risk factors Leading 
to  Diabetes (SHIELD) showed that 28% of individuals 
with T2DM are overweight (body mass index [BMI]: 
25–29.99 kg/m2) and 59% are obese (BMI $ 30 kg/m2).49 
These associations are consistent for men and women and 
across racial and ethnic groups.50 Obesity and associated SC 
fat may slow insulin absorption and reduce exposure, altering 
the PK profile. Obese patients may also require higher starting 
insulin doses due to obesity-associated IR,51 but results sug-
gest that these effects vary across currently available insulin 
analogs. The effects of obesity on the PK/PD of glargine and 
detemir have not been studied, but have been assessed for the 
rapid-acting insulin analogs. It has been reported that there 
International Journal of General Medicine 2011:4submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
832
Morello
is a significant correlation (r = 0.42, 95% CI: 0.02–0.82) 
between BMI and time to maximum activity for lispro.
A study in subjects using aspart showed that increasing 
obesity was significantly correlated with decreased apparent 
clearance per kg body weight (P = 0.002), increased elimination 
half-life (P = 0.044), and elevated AUC (P = 0.006). However, 
it was also noted that these changes were not as great as 
within-subject variability for these PK parameters.52 The 
prescribing information for aspart also notes that clearance is 
reduced by 28% in patients with BMI . 32 kg/m2 versus those 
with BMI , 23 kg/m2.20 Published results have indicated no 
significant correlation between BMI and time to maximum 
activity for glulisine (r = 0.13, 95% CI: -0.33–0.59),13 but 
the PI for glulisine does state that obesity increases T
max
 from 
60 minutes to 85 minutes.21
Renal dysfunction
Approximately 20% of patients with diabetes have renal 
dysfunction,53 and understanding the effects of this com-
mon complication on the PK and actions of insulin in these 
patients is important. Insulin levels are increased in patients 
with diabetes and overt nephropathy because 30%–80% of 
circulating insulin is removed by renal excretion. However, 
the metabolic response to insulin (ie, its effect on PG) is 
decreased in this population.54 It has also been suggested 
that insulin dosing be decreased in patients with diabetes 
who have end-stage renal disease, and who are undergoing 
hemodialysis because they are at increased hypoglycemia 
risk.55 Insulin requirements in these patients may change 
due to metabolic alterations influencing PK and PD. The 
prescribing information for detemir indicates no change in 
PK or PD in patients with renal impairment (RI), although 
frequent self-monitoring of blood glucose is recommended 
and dose adjustments may be necessary.4
The effects of RI on the PK and actions of glargine have 
not been studied.23 For the rapid-acting insulin analogs, there is 
an increased PD effect of lispro (ie, elevated glucose-lowering 
response) as renal function declines,19 and renal dysfunction 
does not alter the PK of aspart.20,52 Results for glulisine indicate 
that subjects with moderate and severe RI have 29% and 40% 
increases in insulin exposure and 20% and 25% reductions 
in clearance, respectively, versus those with normal renal 
function.21 Therefore, glulisine should be empirically reduced 
in patients with renal insufficiency to prevent hypoglycemia.
Hepatic dysfunction
The liver plays a central role in maintaining normal glucose 
concentrations in individuals without diabetes and mediates 
several processes, including hepatic glucose output and 
uptake. Changes in hepatic function may also affect the 
glucose-lowering effects of insulin.56 Results for detemir 
indicate that patients with severe hepatic dysfunction and 
without diabetes have lower AUC values compared with 
healthy controls.4 The effects of hepatic dysfunction on 
the PK/PD of glargine have not been studied.23 Available 
information indicates no effects of hepatic impairment on the 
PK of either lispro or aspart,19,20,52 while the effects of liver 
dysfunction on the PK of glulisine have not been studied.21
Pregnancy
Results from older PK studies indicate that the PK of insulin 
are not altered during pregnancy.57 However, IR is increased 
during pregnancy, and this may require a higher insulin 
dose.57,58 At present, there is no information about the effects 
of pregnancy on the PK/PD of any of the insulin analogs.
exercise
Any factor that alters blood flow is also likely to alter insulin 
absorption, with greater blood flow being associated with 
more rapid insulin absorption. Conditions that modify local 
blood flow include exercise, massage, bathing in warm 
water, and the use of vasodilating or vasoconstricting drugs.59 
However, significant effects of these activities have not 
been invariably observed with all insulin analogs. Results 
from a study of 13 patients with T1DM who exercised for 
30 minutes, then had radiolabeled glargine injected into the 
thigh, indicated no increase in the decay of radioactivity 
versus results obtained after injection without exercise.60
Results from a study of eight patients with T1DM who 
were treated with a standard dose of lispro before a meal 
of 600 kcal (75 g carbohydrate) and who, 90 minutes later, 
undertook postprandial exercise at 25% maximum oxygen 
consumption (VO
2 max
) for 60 minutes, 50% VO
2 max
 for 30 
and 60 minutes, and 75% VO
2 max
 for 30 minutes, indicated 
increased risk for hypoglycemia at all exercise intensities.61 
A reduced lispro dose or a pre-exercise snack should be 
considered before exercise to prevent low-BG events. It 
is reasonable to suggest that this recommendation should 
also be applied for patients taking other rapid-acting insulin 
analogs.
Drug interactions with insulin analogs
Patients with T2DM are likely to have comorbid  conditions 
(eg, hypertension, dyslipidemia), which require chronic 
pharmacologic treatment.62 Insulin treatment in these 
patients requires attention to drug interactions that may 
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alter insulin PK/PD. Information about interactions between 
 insulin and other medications is scarce; specific drug inter-
actions are not listed in the PIs for the insulin analogs. This 
advice has been provided, however: drugs that potentially 
increase the BG-lowering effect of insulins and suscepti-
bility to hypoglycemia include oral antidiabetic products, 
pramlintide, angiotensin-converting enzyme inhibitors, 
disopyramide, fibrates, fluoxetine, monoamine oxidase 
inhibitors, propoxyphene, pentoxifylline, salicylates, soma-
tostatin analogs, and sulfonamide antibiotics. Drugs that 
potentially reduce the BG-lowering effect of insulins include 
corticosteroids, niacin, danazol, diuretics, sympathomimetic 
agents (eg, epinephrine, albuterol, terbutaline), glucagon, 
isoniazid, phenothiazine derivatives, somatropin, thyroid hor-
mones, estrogens, progestogens (eg, in oral contraceptives), 
 protease inhibitors, and atypical antipsychotic medications 
(eg, olanzapine and clozapine). Increased self-monitoring of 
BG and closer follow-up are required in patients taking these 
medications, and insulin doses should be adjusted based on 
pattern management of 1–2 weeks of patient glucose logbook 
records.19–21,23
Conclusion
Many patients with T2DM will require insulin therapy to 
maintain glycemic control. Management of these patients 
has been facilitated by development of rapid-acting and 
long-acting insulin analogs, which can be combined to more 
closely mimic physiologic insulin secretion. PK/PD for 
insulin analogs may be influenced by age, weight, ethnicity 
or race, pregnancy, activity level, and hepatic and renal 
function (Table 2).4,13,19–21,23,24,29,32,37,38,40–61 However, these 
variables do not have equivalent effects on all rapid-acting 
or long-acting insulin analogs. While some effects on PK/PD 
of insulin analogs may seem subtle, they may account for 
the difficulties encountered by providers when establishing 
glycemic control. Patients with characteristics potentially 
affecting insulin PK/PD may require dosing alterations 
and closer monitoring than others with T2DM receiving 
insulin therapy. Because all these factors may affect PK/PD 
parameters, individualized monitoring is imperative to reach 
glucose goals effectively and safely and decrease the risks 
of long-term hyperglycemia.
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Table 2 variables and potential effects on insulin analog dosing
Variable Potential effect Action needed*
Insulin dose24,37,38 Duration of action increases with increasing doses Dose adjustments should be more conservative  
as the administered dose increases
Injection site21,23,29,32,40–43 Absorption varies with site of injection, heat,  
muscle activity; abdomen has least variability
Rotate injection sites within the same body region  
to decrease variability and improve predictability  
of response
Older age4,44,45 Increased insulin effects with possible decreased  
clearance and increased AUC
Match carbohydrate meal content to insulin dose  
for rapid-acting insulins; initial dose and dose  
adjustments should be conservative
Racial and ethnic groups4,21,46–48 No difference in absorption for detemir or aspart;  
more rapid absorption for glargine and higher initial  
exposure for glulisine in Japanese patients
Data are limited; no adjustment needed for detemir 
or aspart; adjustments may be needed for Japanese  
patients receiving glargine or glulisine
Obesity13,20,21,49–51 Slower absorption and reduced exposure of insulin  
analogs with increased subcutaneous fat; decreased  
clearance may occur with some insulin analogs
Higher starting doses may be required because  
of insulin resistance, but not consistent across  
insulin analogs
Renal dysfunction4,19–21,23,52–55 Insulin clearance decreased, insulin levels increase,  
metabolic responses to insulin decrease
Dose requirements may decrease for patients  
with moderate to severe renal dysfunction
Hepatic dysfunction4,19–21,23,52,56 Data are limited; hepatic clearance of insulin  
decreased
Dose requirements may decrease in severe hepatic  
dysfunction and be unchanged in mild to moderate  
dysfunction
Pregnancy57,58 No data available for insulin analogs;  
insulin resistance increased
Dose requirements may increase
exercise59–61 Increased absorption possible from muscle sites May need to reduce doses of rapid-acting  
analogs before exercise
Note: *Frequent self-monitoring of blood glucose is recommended for patients with any of these variables (which could potentially affect insulin analog dosing) until the 
patient is on a stable dose of the insulin analog.
Abbreviation: AUC, area under the curve.
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